Preliminary clinical data showing Takeda Pharmaceutical Co. Ltd.’s gut-selective biologic, vedolizumab (Entyvio), was superior to AbbVie Inc.’s anti-TNF biologic Humira (adalimumab) in achieving clinical remissions in patients with moderate-to-severe active ulcerative colitis could have important implications for clinical practice, and also commercially for the therapeutic sector.
The VARSITY study is thought to be one of the first head-to-head blinded comparisons of two biologics in inflammatory bowel...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
